Skip to main content
Dan Iosifescu, MD, Psychiatry, New York, NY, NYU Langone Hospitals

DanVladIosifescuMD

Psychiatry • New York, NY

Professor of Psychiatry, NYU School of Medicine and Director, Clinical Research Division, Nathan Kline Institute

Join to view full profile

Dr. Iosifescu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Iosifescu's full profile

Already have an account?

Summary

  • Dr. Dan Iosifescu is a psychiatrist in New York, NY and is affiliated with NYU Langone Health. He received his medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 33 years. His clinical expertise is primarily focused on mood disorders ((bipolar disorder, treatment-resistant depression). His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as photobiomodulation with near infrared light and novel forms of magnetic stimulation) for patients with severe mood disorders and Alzheimer's disease. In his research Dr. Iosifescu uses neuroimaging (MRI, MRS, PET) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities and their impact on clinical treatment. Dr. Iosifescu has more than 200 publications and over 500 abstracts.

Education & Training

  • Harvard Medical School and Massachusetts Institute of Technology
    Harvard Medical School and Massachusetts Institute of TechnologyMaster of Medical Science (M.M.Sc.), Clinical Investigation, 2001 - 2003
  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2000
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1996 - 1997
  • Carol Davila University of Medicine and Pharmacy
    Carol Davila University of Medicine and PharmacyClass of 1992

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • MA State Medical License
    MA State Medical License 1998 - 2025
  • NY State Medical License
    NY State Medical License 2009 - 2025
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients with Major Depressive Disorder  
    Katherine A Collins, Dan V Iosifescu, James W Murrough, Eric J Nestler, Nisha Chadha, Nature
  • Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)  
    Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature

Authored Content

  • Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
  • Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
  • F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
  • F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
  • Join now to see all

Press Mentions

  • Axsome Therapeutics Receives FDA Nod for Auvelity
    Axsome Therapeutics Receives FDA Nod for AuvelitySeptember 7th, 2022
  • FDA Approves First Fast-Acting Oral Drug for Clinical Depression That Works in 1 Week
    FDA Approves First Fast-Acting Oral Drug for Clinical Depression That Works in 1 WeekAugust 25th, 2022
  • Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder?
    Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder?July 12th, 2022
  • Join now to see all

Grant Support

  • Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2010–2011
  • Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2008–2009
  • Depression And Brain MetabolismNational Institute Of Mental Health2003–2007

Hospital Affiliations

Dr. Dan Iosifescu, Dr. Dan Iosifescu, MD, Dr. D Iosifescu, Dr. Dan Vlad Iosifescu